INSTYTUT FARMACEUTYCZNY Patent applications |
Patent application number | Title | Published |
20150031898 | PROCESS FOR PREPARATION OF PROSTAGLANDIN F2 ALPHA ANALOGUES - A convergent synthesis of the prostaglandin F | 01-29-2015 |
20140107051 | ISOFLAVONES FOR TREATING MUCOPOLYSACCHARIDOSES - A pharmaceutical composition including a pharmaceutically acceptable excipient; and a natural isoflavone of formula (I), a derivative thereof, or a pharmaceutically acceptable salt thereof, the natural isoflavone, the derivative thereof, or the pharmaceutically acceptable salt thereof being in a therapeutically effective amount for the treatment of mucopolysaccharidosis. A method of treatment of mucopolysaccharidosis, the method including administering to a patient in the need of such treatment—a therapeutically effective amount of a natural isoflavone of formula (I), a derivative thereof, or a pharmaceutically acceptable salt thereof. | 04-17-2014 |
20130190538 | PROCESS FOR THE PREPARATION OF PROTOESCIGENIN - A process for the preparation of protoescigenin by hydrolysis of escin isolated from | 07-25-2013 |
20130006003 | NEW SYNTHONES FOR PREPARATION OF 19-NOR VITAMIN D DERIVATIVES - The present invention discloses the synthone of Formula (I), wherein R | 01-03-2013 |
20120190642 | ISOFLAVONES FOR TREATING MUCOPOLYSACCHARIDOSES - A method of treatment of mucopolysaccharidosis, the method including administering to a patient in the need of such treatment—a therapeutically effective amount of a natural isoflavone of formula (I), a derivative thereof, or a pharmaceutically acceptable salt thereof. A pharmaceutical composition including a pharmaceutically acceptable excipient; and a natural isoflavone of formula (I), a derivative thereof, or a pharmaceutically acceptable salt thereof, the natural isoflavone, the derivative thereof, or the pharmaceutically acceptable salt thereof being in a therapeutically effective amount for the treatment of mucopolysaccharidosis. | 07-26-2012 |
20120101057 | COMBINED THERAPY OF COLORECTAL CARCINOMA - The invention relates to a combined therapy, wherein addition of a vitamin D analogue to the standard treatment regimen based on cytostatics, 5-fluorouracil and/or its precursors, generates potential possibility of achieving beneficial therapeutic effect in the first-line chemotherapy or adjuvant therapy of colorectal carcinoma. Vitamin D analogues are selected from a group consisting of tacalcitol, calcipotriol and 5,6-trans-isomer of calcipotriol. | 04-26-2012 |
20100222614 | PROCESS FOR THE PREPARATION OF CALCIPOTRIOL - A process for the preparation of calcipotriol at least including: (a) reacting a C-22 phenylsulfonyl derivative of cholecalciferol of Formula 2, wherein R | 09-02-2010 |
20090105483 | PROCESS FOR THE PREPARATION OF PRAMIPEXOLE BASE AND/OR ITS SALTS - The process for the preparation of pramipexole base and/or its pharmaceutically acceptable salts, especially the hydrochloride salt, in the alkylation reaction of (S)-(−)2,6-diamino-4,5,6,7-tetrahydrobenzothiazole with an alkylating agent, wherein the reaction is carried out in the absence of a base, and in a solvent from which the resulting N-monoalkylated product selectively precipitates out as a salt. After isolation from the reaction mixture, the N-monoalkylated product is converted a) into the free pramipexole base upon treatment with an inorganic base and is then converted into another pharmaceutically acceptable pramipexole salt; or b) directly into another pharmaceutically acceptable pramipexole salt or the hydrate thereof. | 04-23-2009 |
20090093651 | PROCESS FOR PREPARATION OF 13,14-DIHYDRO-PGF2 ALPHA DERIVATIVES - The invention relates to a process for the preparation of 13,14-dihydro-PGF | 04-09-2009 |
20090062380 | ISOFLAVONES FOR TREATING MUCOPOLYSACCHARIDOSES - The invention relates to the medical use of natural isoflavones and their semisynthetic derivatives or the pharmaceutically acceptable salts thereof for the therapeutic and/or prophylactic treatment of diseases, at the base of which lies an excessive production or storage of glycosaminoglycans, especially for treatment of mucopolysaccharidoses. The isoflavones and their semisynthetic derivatives are represented by formula (I), in which R | 03-05-2009 |
20090005413 | Novel Salt of Montelukast - The invention relates to a novel salt of montelukast with tert-butylamine and its use in the process for the preparation of highly pure free montelukast acid and/or pharmaceutically acceptable salts thereof, in particular montelukast sodium. | 01-01-2009 |
20080255380 | Process and Intermediates for the Preparation of Sulfonyl Derivatives of Cholecalciferol - Preparation of sulfonyl derivatives of cholecalciferol of Formula 1, wherein R | 10-16-2008 |
20080234493 | Process for the Preparation of 2-[N-[{S)-1-Ethoxycarbonyl-3-Phenylpropyl]-(S)-Alanyl]-(1S,3S,5S)-2-Azabicyclo[3.3.0]Oct- an-3-Carboxylic Acid - A process for preparation of 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-(S)-alanyl]-(1S,3S,5S)-2- azabicyclo [3.3.0] octane-3-carboxylic acid, ie. Ramipril, involves condensation of an activated derivative of 2-[N-](S)-1-ethoxycarbonyl-3-phenylpropyl]-(S)-alanine with racemic (1R*,3R*,5R*)-2-azabicyclo[3.3.0]octane-3-carboxylic acid, and then the desired diastereoisomer (1a) is separated from the obtained diastereoisomeric mixture of 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl](S)-alanyl]-(1S,3S,5S)-2-azabicyclo[3.3.0]octane-3-carboxylic acid (1a) and 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl -alanyl]-(1R,3R,5R)-2-azabicyclo[3.3.0]octane-3-carboxylic acid (1b) by treating it with a solvent that selectively dissolves the undesired diastereoisomer (1b) while the diastereoisomer (1a) remains undissolved. | 09-25-2008 |
20080214876 | Process for Preparation of Pharmaceutically Pure Anhydrous Calcipotriol - A process for the preparation of a pharmaceutical-grade anhydrous calcipotriol comprising: (a) dissolving crude calcipotriol having a water content of X % by weight in a first solvent or in a mixture of two or more first solvents, said first solvent or said mixture of two or more first solvents forming an azeotropic system with water, to obtain a solution of crude calcipotriol; (b) obtaining an intermediate calcipotriol by (i) placing said solution of crude calcipotriol under a reduced pressure and evaporating, if X is greater than or equal to 1, or (ii) crystallizing, if X is lower than 1; and (c) re-dissolving said intermediate calcipotriol in a second solvent or a mixture of two or more second solvents, said second solvent being anhydrous, and crystallizing at least once to obtain pharmaceutical-grade anhydrous calcipotriol. | 09-04-2008 |
20080207926 | PROCESS FOR PREPARATION OF 13,14-DIHYDRO-PGF2 ALPHA DERIVATIVES - The invention relates to a process for the preparation of 13,14-dihydro-PGF | 08-28-2008 |